PL3345895T3 - Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby - Google Patents

Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby

Info

Publication number
PL3345895T3
PL3345895T3 PL17204895T PL17204895T PL3345895T3 PL 3345895 T3 PL3345895 T3 PL 3345895T3 PL 17204895 T PL17204895 T PL 17204895T PL 17204895 T PL17204895 T PL 17204895T PL 3345895 T3 PL3345895 T3 PL 3345895T3
Authority
PL
Poland
Prior art keywords
disease
treatment
benzoic acid
acid compound
nonsense suppression
Prior art date
Application number
PL17204895T
Other languages
English (en)
Inventor
Gary Mitchell Karp
Seongwoo Hwang
Guangming Chen
Neil Gregory Almstead
Young-Choon Moon
Original Assignee
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics, Inc. filed Critical Ptc Therapeutics, Inc.
Publication of PL3345895T3 publication Critical patent/PL3345895T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL17204895T 2003-04-11 2004-04-09 Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby PL3345895T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US46198803P 2003-04-11 2003-04-11
EP14188816.4A EP2910551B1 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
EP17204895.1A EP3345895B1 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
EP17153046.2A EP3178816A1 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
PCT/US2004/011106 WO2004091502A2 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compounds
EP04759404.9A EP1618098B1 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease

Publications (1)

Publication Number Publication Date
PL3345895T3 true PL3345895T3 (pl) 2020-05-18

Family

ID=33299886

Family Applications (7)

Application Number Title Priority Date Filing Date
PL16170630T PL3103800T3 (pl) 2003-04-11 2004-04-09 Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PL14188816T PL2910551T3 (pl) 2003-04-11 2004-04-09 Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PL17204895T PL3345895T3 (pl) 2003-04-11 2004-04-09 Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PL21169137.3T PL3889142T3 (pl) 2003-04-11 2004-04-09 Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji nonsensu i do leczenia choroby
PL19209758T PL3632902T3 (pl) 2003-04-11 2004-04-09 Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PL19174887T PL3549936T3 (pl) 2003-04-11 2004-04-09 Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PL04759404T PL1618098T3 (pl) 2003-04-11 2004-04-09 Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do tłumienia mutacji nonsensownych i leczenia chorób

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL16170630T PL3103800T3 (pl) 2003-04-11 2004-04-09 Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PL14188816T PL2910551T3 (pl) 2003-04-11 2004-04-09 Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby

Family Applications After (4)

Application Number Title Priority Date Filing Date
PL21169137.3T PL3889142T3 (pl) 2003-04-11 2004-04-09 Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji nonsensu i do leczenia choroby
PL19209758T PL3632902T3 (pl) 2003-04-11 2004-04-09 Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PL19174887T PL3549936T3 (pl) 2003-04-11 2004-04-09 Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby
PL04759404T PL1618098T3 (pl) 2003-04-11 2004-04-09 Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do tłumienia mutacji nonsensownych i leczenia chorób

Country Status (29)

Country Link
US (17) US6992096B2 (pl)
EP (9) EP3178816A1 (pl)
JP (2) JP4851933B2 (pl)
KR (1) KR101134188B1 (pl)
CN (2) CN1802360B (pl)
AU (1) AU2004229487B9 (pl)
BE (1) BE2015C025I2 (pl)
BR (1) BRPI0409319B8 (pl)
CA (1) CA2521992C (pl)
CR (1) CR8086A (pl)
CY (7) CY1115870T1 (pl)
DK (7) DK3103800T3 (pl)
EA (1) EA009120B1 (pl)
ES (7) ES2624610T3 (pl)
FR (1) FR15C0030I2 (pl)
HU (7) HUE055056T2 (pl)
IL (2) IL171343A (pl)
LU (1) LU92698I2 (pl)
MA (1) MA27802A1 (pl)
MX (1) MXPA05010747A (pl)
NO (2) NO332843B1 (pl)
NZ (1) NZ543263A (pl)
PL (7) PL3103800T3 (pl)
PT (7) PT3889142T (pl)
SI (7) SI3103800T1 (pl)
TR (1) TR201706226T4 (pl)
UA (1) UA84420C2 (pl)
WO (1) WO2004091502A2 (pl)
ZA (1) ZA200508298B (pl)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
WO2004010106A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP3178816A1 (en) * 2003-04-11 2017-06-14 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
AU2005295730A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
JP5800451B2 (ja) * 2005-04-08 2015-10-28 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物
AU2012238226B2 (en) * 2005-04-08 2015-05-14 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CN100378084C (zh) * 2005-08-01 2008-04-02 安徽大学 2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途
AU2007212201B2 (en) * 2006-02-09 2012-09-13 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
CN101505739A (zh) * 2006-03-30 2009-08-12 Ptc医疗公司 由具有无义突变的dna生产功能蛋白的方法以及相关疾病的治疗
BRPI0710839A2 (pt) * 2006-04-06 2011-08-23 Prosidion Ltd agonistas heterocìclicos de gpcr
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007130499A2 (en) * 2006-05-01 2007-11-15 Virobay, Inc. Antiviral agents
DK2059513T3 (da) * 2006-09-08 2013-05-06 Ptc Therapeutics Inc Fremgangsmåde til fremstillingen af 1,2,4-oxadiazolbenzoesyrer
AU2007300542B2 (en) * 2006-09-25 2012-05-17 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
WO2008130370A1 (en) * 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
AU2013219243B2 (en) * 2006-10-12 2016-09-08 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
EP2073805B1 (en) * 2006-10-12 2015-03-04 PTC Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
AU2016262645B2 (en) * 2006-10-12 2018-05-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
JP2010513283A (ja) * 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
KR20100016073A (ko) * 2007-04-02 2010-02-12 인스티튜트 포 원월드 헬스 Ｃｆｔｒ 억제제 화합물 및 이의 용도
AU2008267894B2 (en) * 2007-06-22 2012-08-23 F. Hoffmann-La Roche Ag Isoxazole-imidazole derivatives
EP2167508A1 (en) * 2007-07-23 2010-03-31 Summit Corporation Plc Compounds for treating duchenne muscular dystrophy
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
TWI577285B (zh) 2007-08-13 2017-04-11 孟山都科技有限責任公司 控制植物寄生性線蟲的化合物及方法以及被覆有該化合物之種子
JP5727223B2 (ja) 2007-10-04 2015-06-03 メルク セローノ ソシエテ アノニム オキサジアゾール・ジアリール化合物
US8202865B2 (en) * 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
ES2556080T3 (es) 2007-11-16 2016-01-12 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
CN101952276B (zh) * 2007-12-07 2014-10-22 Abbvie德国有限责任两合公司 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途
CA2707671C (en) * 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
UA102534C2 (xx) 2007-12-07 2013-07-25 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ)
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
EP2250165B1 (en) * 2007-12-21 2018-07-25 Merck Serono S.A. Triazole oxadiazoles derivatives
JP5279728B2 (ja) * 2007-12-25 2013-09-04 キッセイ薬品工業株式会社 新規なカテコール誘導体
CA2714370C (en) 2008-02-07 2017-05-02 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
NZ616097A (en) 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
EP2278879B1 (en) 2008-04-21 2016-06-15 PATH Drug Solutions Compounds, compositions and methods comprising oxadiazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2009131952A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising thiazole derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131956A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazole derivatives
WO2009131954A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
CA2726999C (en) * 2008-06-09 2017-05-02 Ludwig-Maximilians-Universitaet Muenchen New drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
BRPI0914629A2 (pt) * 2008-06-24 2019-09-24 Irm Llc compostos e métodos para a modulação de receptores acoplados à proteína g
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
EP2396321B1 (en) 2009-02-10 2015-05-06 Monsanto Technology LLC Compositions and methods for controlling nematodes
JP5620129B2 (ja) * 2009-03-19 2014-11-05 富士フイルム株式会社 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物
RU2398770C1 (ru) * 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2251437B1 (en) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US9849146B2 (en) * 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
CA2770082C (en) * 2009-08-05 2014-09-30 International Paper Company Dry fluff pulp sheet additive
HUE054000T2 (hu) 2009-11-13 2021-08-30 Receptos Llc Szelektív szfingozin-1-foszfát-receptor modulátorok és királis szintézis eljárások
ES2665461T3 (es) 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
RU2711481C2 (ru) 2010-03-25 2020-01-17 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
NZ602795A (en) 2010-04-07 2015-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN102917692A (zh) 2010-04-07 2013-02-06 弗特克斯药品有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2600865B1 (en) * 2010-08-05 2018-11-14 Université de Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
WO2012027247A2 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
CN103732213A (zh) 2011-06-07 2014-04-16 帕里昂科学公司 治疗方法
WO2012170371A1 (en) * 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR101314488B1 (ko) * 2011-09-08 2013-10-07 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도
AU2012335714B2 (en) 2011-11-08 2017-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20130186801A1 (en) 2012-01-25 2013-07-25 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2828249B1 (en) 2012-03-23 2018-10-10 The Regents of The University of California Premature-termination-codons readthrough compounds
EP3366680B1 (en) 2012-05-29 2020-05-13 Parion Sciences, Inc. Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
ES2782509T3 (es) 2012-07-02 2020-09-15 Monsanto Technology Llc Procedimiento para la preparación de 1,2,4-oxadiazoles 3,5-disustituidos
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
PL2914248T5 (pl) 2012-11-02 2024-01-15 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR
PE20151062A1 (es) 2012-12-13 2015-08-05 Novartis Ag PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO
CN104995178B (zh) 2012-12-17 2018-06-26 帕里昂科学公司 3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
TWI636978B (zh) * 2014-03-06 2018-10-01 美商Ｐｔｃ治療公司 １，２，４－二唑苯甲酸之鹽及醫藥組合物
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
CA2944140C (en) 2014-04-15 2022-10-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US9896448B2 (en) 2014-06-03 2018-02-20 Novartis Ag Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
US9884862B2 (en) 2014-06-03 2018-02-06 Novartis Ag Pyridopyrimidinedione derivatives
CU24438B1 (es) 2014-06-03 2019-09-04 Novartis Ag Compuestos derivados de 1,6 naftiridina-diona activos como supresores de mutación sin sentido
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
AU2015328174B2 (en) 2014-10-06 2020-05-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN104292180A (zh) * 2014-10-12 2015-01-21 湖南华腾制药有限公司 一种恶二唑衍生物的制备方法
US10174012B2 (en) 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016097004A1 (en) * 2014-12-17 2016-06-23 King's College London BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
KR20180081516A (ko) * 2015-10-30 2018-07-16 피티씨 테라퓨틱스, 인크. 간질 치료 방법
WO2017087364A1 (en) 2015-11-16 2017-05-26 Ptc Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxandiazole benzoic acid compounds, compositions and uses thereof
CA3048193A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
CN106279057B (zh) * 2016-08-15 2022-04-15 广州明药科技有限公司 Ataluren的合成方法
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018050706A1 (en) 2016-09-13 2018-03-22 Marco Cipolli Method of treatment of shwachman-diamond syndrome
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
WO2020078894A1 (en) 2018-10-15 2020-04-23 Academisch Medisch Centrum Oncotherapeutic combinations
KR102658031B1 (ko) * 2018-12-27 2024-04-18 제이투에이치바이오텍 (주) 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체
KR20210151131A (ko) * 2019-04-10 2021-12-13 피티씨 테라퓨틱스, 인크. 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN111675672A (zh) * 2020-05-12 2020-09-18 石家庄市度智医药科技有限公司 一种制备阿塔鲁伦的方法
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
CN116217508B (zh) * 2022-12-15 2024-12-17 浙江工业大学 一类用于保护β细胞来治疗II型糖尿病的噁二唑类化合物及其制备方法和应用
US11932632B1 (en) 2023-10-13 2024-03-19 King Faisal University N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound
US11958814B1 (en) 2023-11-02 2024-04-16 King Faisal University 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound
CN119638642A (zh) * 2023-12-12 2025-03-18 暨南大学 双环类化合物及其药物组合物和应用
WO2025243250A1 (en) * 2024-05-23 2025-11-27 Biophore India Pharmaceuticals Pvt. Ltd. A process for the preparation of 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (pl) * 1962-04-17
US3325446A (en) * 1964-04-17 1967-06-13 Allied Chem Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en) 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) * 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4166732A (en) 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4135910A (en) * 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4165910A (en) * 1977-10-25 1979-08-28 Bunker Ramo Corporation Electrical connector
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
DE3173083D1 (en) * 1980-03-22 1986-01-16 Fbc Ltd Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4320801A1 (de) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6071700A (en) * 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
ATE218381T1 (de) 1995-03-14 2002-06-15 Siemens Ag Ultraschall-zerstäuber mit abnehmbarer präzisionsdosiereinheit
US5950619A (en) 1995-03-14 1999-09-14 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
TR199800414T1 (xx) 1995-09-07 1998-05-21 Novartis Ag De�i�tirilmi� fosfinik bile�ikler ve ila� olarak kullan�m�.
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
CN1216534A (zh) * 1996-04-26 1999-05-12 日本曹达株式会社 杂环取代的新颖苯衍生物和除草剂
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
EP0975595B9 (en) 1997-04-07 2009-09-16 Georgetown University Analogs of cocaine
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
AU9647998A (en) * 1997-10-27 1999-05-17 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
NZ506289A (en) 1998-03-16 2004-12-24 Nektar Therapeutics Aerosolized active agent delivery to the lungs at a flow rate of less than 17 liters per minute
AU750369B2 (en) 1998-04-23 2002-07-18 Cortech, Inc. Cysteine protease inhibitors
BR9914370A (pt) 1998-10-08 2001-11-27 Smithkline Beecham Plc Derivados de tetraidrobenzazepina úteis comomoduladores de receptores para a dopamina d3(agentes antipsicóticos)
CA2346396C (en) 1998-10-09 2009-04-28 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
WO2000025768A1 (en) 1998-10-29 2000-05-11 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
CN1253441C (zh) 1998-12-23 2006-04-26 史密丝克莱恩比彻姆公司 蛋白酶抑制剂
WO2000058278A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives d'acides amines $g(b)
AU3196100A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
WO2000058280A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
CZ20013767A3 (cs) 1999-05-17 2002-04-17 Novo Nordisk A/S Sloučenina, farmaceutický prostředek, pouľití sloučeniny a způsob léčení
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
CA2402414A1 (en) 2000-03-22 2001-09-27 Christopher Bayly Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
AU2001248765A1 (en) * 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
HU227630B1 (hu) 2000-05-22 2011-10-28 Aventis Pharma Inc Arilmetilamin-származékok triptáz gátlóként való alkalmazásra és ezeket tartalmazó gyógyszerkészítmények
CN1328143A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人甲基化－dna－蛋白－半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
ES2252455T3 (es) 2001-04-19 2006-05-16 Bayer Healthcare Ag Arilsulfonamidas como agentes antivirales.
AU2002313633B2 (en) * 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
JP2003081832A (ja) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
US20040132726A1 (en) 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
MXPA05001590A (es) 2002-08-09 2005-05-23 Astrazeneca Ab Compuestos que tienen actividad en los receptores metabotropicos de glutamato.
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
KR100729883B1 (ko) 2003-03-28 2007-06-18 화이자 프로덕츠 인코포레이티드 죽상경화증 및 비만증을 치료하기 위한 ｃｅｔｐ억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체
EP3178816A1 (en) * 2003-04-11 2017-06-14 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AU2005295730A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
JP5800451B2 (ja) * 2005-04-08 2015-10-28 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物
CN101505739A (zh) 2006-03-30 2009-08-12 Ptc医疗公司 由具有无义突变的dna生产功能蛋白的方法以及相关疾病的治疗
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
DK2059513T3 (da) 2006-09-08 2013-05-06 Ptc Therapeutics Inc Fremgangsmåde til fremstillingen af 1,2,4-oxadiazolbenzoesyrer
AU2007300542B2 (en) 2006-09-25 2012-05-17 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
EP2073805B1 (en) 2006-10-12 2015-03-04 PTC Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
PL2203173T3 (pl) 2007-10-26 2016-06-30 Academisch Ziekenhuis Leiden Środki i sposoby przeciwdziałania zaburzeniom mięśni
ES2436781T3 (es) 2007-12-17 2014-01-07 The Regents Of The University Of Michigan Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético
BRPI0914629A2 (pt) 2008-06-24 2019-09-24 Irm Llc compostos e métodos para a modulação de receptores acoplados à proteína g
NO2344129T3 (pl) 2008-10-07 2018-07-21
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота

Also Published As

Publication number Publication date
CY2015017I1 (el) 2016-06-22
EP3549936B1 (en) 2021-06-02
US7202262B2 (en) 2007-04-10
AU2004229487B2 (en) 2010-05-20
US20100168109A1 (en) 2010-07-01
EP3103800B1 (en) 2018-06-13
KR101134188B1 (ko) 2012-04-12
EP3103800A1 (en) 2016-12-14
PL3889142T3 (pl) 2022-09-26
EP3889142A1 (en) 2021-10-06
US20140301978A1 (en) 2014-10-09
WO2004091502A2 (en) 2004-10-28
DK3345895T3 (da) 2020-02-03
AU2004229487A1 (en) 2004-10-28
PT3103800T (pt) 2018-07-27
US7419991B2 (en) 2008-09-02
NZ543263A (en) 2008-12-24
US20060035943A1 (en) 2006-02-16
TR201706226T4 (tr) 2018-06-21
US9861617B2 (en) 2018-01-09
US9205088B2 (en) 2015-12-08
HUE047569T2 (hu) 2020-04-28
EP2910551A1 (en) 2015-08-26
US20070161687A1 (en) 2007-07-12
PT3345895T (pt) 2020-01-29
BRPI0409319B1 (pt) 2019-11-12
CA2521992A1 (en) 2004-10-28
CY1119001T1 (el) 2018-01-10
PL3549936T3 (pl) 2021-11-08
WO2004091502A3 (en) 2004-12-29
EP4101846A1 (en) 2022-12-14
ES2887054T3 (es) 2021-12-21
ES2528195T3 (es) 2015-02-05
HUS1500021I1 (hu) 2017-04-28
FR15C0030I2 (fr) 2015-07-24
US20160081988A1 (en) 2016-03-24
HK1202254A1 (en) 2015-09-25
US7772259B2 (en) 2010-08-10
EP1618098A2 (en) 2006-01-25
FR15C0030I1 (pl) 2015-05-22
PT3549936T (pt) 2021-07-14
MA27802A1 (fr) 2006-03-01
PT3632902T (pt) 2021-09-15
DK2910551T3 (en) 2017-05-15
SI3345895T1 (sl) 2020-03-31
NO2015002I1 (no) 2015-02-16
WO2004091502A8 (en) 2005-11-24
JP4851933B2 (ja) 2012-01-11
CY1122659T1 (el) 2020-10-14
US20100216851A1 (en) 2010-08-26
ES2679108T3 (es) 2018-08-22
PT1618098E (pt) 2015-02-10
US20110311486A1 (en) 2011-12-22
US8129540B2 (en) 2012-03-06
EP3889142B1 (en) 2022-06-15
US20040204461A1 (en) 2004-10-14
US8975287B2 (en) 2015-03-10
US8227494B2 (en) 2012-07-24
CY1124464T1 (el) 2022-07-22
BRPI0409319A (pt) 2006-04-25
US7683082B2 (en) 2010-03-23
US20180092887A1 (en) 2018-04-05
CA2521992C (en) 2013-02-05
EP3549936A1 (en) 2019-10-09
EP3632902A1 (en) 2020-04-08
US20120178080A1 (en) 2012-07-12
IL225161A (en) 2014-03-31
US6992096B2 (en) 2006-01-31
HUE059464T2 (hu) 2022-11-28
ES2926542T3 (es) 2022-10-26
HK1093979A1 (en) 2007-03-16
HUE031794T2 (en) 2017-08-28
US20130289007A1 (en) 2013-10-31
HUE039026T2 (hu) 2018-12-28
CY1115870T1 (el) 2016-06-22
MXPA05010747A (es) 2006-05-25
DK3103800T3 (en) 2018-07-30
PL3103800T3 (pl) 2018-11-30
US8163782B2 (en) 2012-04-24
US20060148863A1 (en) 2006-07-06
HUE055434T2 (hu) 2021-11-29
CY1120446T1 (el) 2019-07-10
CN104056278B (zh) 2017-01-18
PT3889142T (pt) 2022-08-22
CY2015017I2 (el) 2016-06-22
JP2011251981A (ja) 2011-12-15
DK3632902T3 (da) 2021-09-13
EP3345895A1 (en) 2018-07-11
US20060148864A1 (en) 2006-07-06
HK1257517A1 (en) 2019-10-25
KR20060009838A (ko) 2006-02-01
CY1125544T1 (el) 2024-09-20
US8486982B2 (en) 2013-07-16
US20150148346A1 (en) 2015-05-28
BE2015C025I2 (pl) 2023-08-09
EP1618098A4 (en) 2008-07-16
EP3178816A1 (en) 2017-06-14
US8796322B2 (en) 2014-08-05
US20120277234A1 (en) 2012-11-01
EP3345895B1 (en) 2019-12-04
HK1214253A1 (en) 2016-07-22
SI3632902T1 (sl) 2022-01-31
DK3889142T3 (da) 2022-09-12
CN1802360A (zh) 2006-07-12
CN104056278A (zh) 2014-09-24
US20050164973A1 (en) 2005-07-28
NO2015002I2 (no) 2015-02-03
EA009120B1 (ru) 2007-10-26
EP1618098B1 (en) 2014-11-19
UA84420C2 (ru) 2008-10-27
EP3632902B1 (en) 2021-07-14
DK1618098T3 (en) 2015-01-12
ES2881198T3 (es) 2021-11-29
ES2624610T3 (es) 2017-07-17
PT2910551T (pt) 2017-05-22
JP5436500B2 (ja) 2014-03-05
PL1618098T3 (pl) 2015-04-30
AU2004229487B9 (en) 2010-06-10
NO20055314D0 (no) 2005-11-10
SI2910551T1 (sl) 2017-07-31
BRPI0409319B8 (pt) 2021-05-25
EA200501601A1 (ru) 2006-06-30
DK3549936T3 (da) 2021-07-12
SI3103800T1 (sl) 2018-10-30
US20100121070A1 (en) 2010-05-13
NO20055314L (no) 2006-01-04
IL171343A (en) 2013-06-27
US8299105B2 (en) 2012-10-30
CN1802360B (zh) 2014-05-07
ES2770035T3 (es) 2020-06-30
US7304080B2 (en) 2007-12-04
PL3632902T3 (pl) 2021-12-20
US8017636B2 (en) 2011-09-13
NO332843B1 (no) 2013-01-21
PL2910551T3 (pl) 2017-09-29
SI3889142T1 (sl) 2022-10-28
SI3549936T1 (sl) 2021-09-30
JP2006522826A (ja) 2006-10-05
CR8086A (es) 2006-12-19
SI1618098T1 (sl) 2015-04-30
US10071081B2 (en) 2018-09-11
HUE055056T2 (hu) 2021-10-28
EP4101846B1 (en) 2023-08-02
ZA200508298B (en) 2007-01-31
LU92698I2 (fr) 2015-06-22
EP2910551B1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
PT3103800T (pt) Compostos do ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e o tratamento de doenças
AU2003254157A8 (en) Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
IL196301A0 (en) Medicament for the treatment of hapatitis c
EP1485127A4 (en) ADMINISTRATION OF AGENTS FOR THE TREATMENT OF IGNITION
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PT1532141E (pt) Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazole e sua utilização como antidepressivos
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
IL165851A0 (en) The use of benziselenazolone compounds in the preparation of medicament against ischemic myocardial injury
AU2003266965A1 (en) Use of carboxamides for the treatment of tinnitus
PL378197A1 (pl) Pochodne kwasów indenokarboksylowych oraz ich zastosowanie do leczenia i zapobiegania cukrzycy i dyslipidemii
GB0212790D0 (en) Medicament for the treatment of diabetes
GB0315877D0 (en) Compounds for the treatment of disease
GB0223996D0 (en) Pharmaceutical formulation for the treatment of cardiovascular disease
ZA200308216B (en) Medicament for the treatment of immuno-deficiency conditions.